A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.
Watanabe S, et al. Among authors: honda r.
Eur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2.
Eur J Cancer. 2024.
PMID: 38061214
Clinical Trial.